These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 26336595)

  • 81. Oral treprostinil for the treatment of pulmonary arterial hypertension.
    de Lartigue J
    Drugs Today (Barc); 2014 Aug; 50(8):557-65. PubMed ID: 25187906
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Macitentan and morbidity and mortality in pulmonary arterial hypertension.
    Pulido T; Adzerikho I; Channick RN; Delcroix M; Galiè N; Ghofrani HA; Jansa P; Jing ZC; Le Brun FO; Mehta S; Mittelholzer CM; Perchenet L; Sastry BK; Sitbon O; Souza R; Torbicki A; Zeng X; Rubin LJ; Simonneau G;
    N Engl J Med; 2013 Aug; 369(9):809-18. PubMed ID: 23984728
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Not Available].
    Ushkalova EA; Zyryanov SK; Zatolochina KE
    Kardiologiia; 2018 Nov; 58(11):82-93. PubMed ID: 30625081
    [TBL] [Abstract][Full Text] [Related]  

  • 84. [Prostanoids in the treatment of pulmonary arterial hypertension].
    Başkurt M; Küçükoğlu MS
    Anadolu Kardiyol Derg; 2010 Sep; 10 Suppl 2():2-8. PubMed ID: 20819749
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Macitentan for the treatment of pulmonary arterial hypertension.
    DuBrock HM; Channick RN
    Expert Rev Respir Med; 2014 Aug; 8(4):393-9. PubMed ID: 24998329
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Extended-release oral treprostinil in the management of pulmonary arterial hypertension: clinical evidence and experience.
    Coons JC; Miller T
    Ther Adv Respir Dis; 2018; 12():1753466618766490. PubMed ID: 29609511
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Treatment of pediatric pulmonary arterial hypertension: A focus on the NO-sGC-cGMP pathway.
    Beghetti M; Gorenflo M; Ivy DD; Moledina S; Bonnet D
    Pediatr Pulmonol; 2019 Oct; 54(10):1516-1526. PubMed ID: 31313530
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Overview of Riociguat and Its Role in the Treatment of Pulmonary Hypertension.
    Kenny M; Clarke MM; Pogue KT
    J Pharm Pract; 2022 Jun; 35(3):437-444. PubMed ID: 33084500
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Soluble guanylate cyclase stimulators in pulmonary hypertension.
    Stasch JP; Evgenov OV
    Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
    [TBL] [Abstract][Full Text] [Related]  

  • 90. First-in-child use of the oral soluble guanylate cyclase stimulator riociguat in pulmonary arterial hypertension.
    Spreemann T; Bertram H; Happel CM; Kozlik-Feldmann R; Hansmann G
    Pulm Circ; 2018; 8(1):2045893217743123. PubMed ID: 29099661
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
    Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
    J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
    [TBL] [Abstract][Full Text] [Related]  

  • 92. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats.
    Lang M; Kojonazarov B; Tian X; Kalymbetov A; Weissmann N; Grimminger F; Kretschmer A; Stasch JP; Seeger W; Ghofrani HA; Schermuly RT
    PLoS One; 2012; 7(8):e43433. PubMed ID: 22912874
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Update on pharmacotherapy for pulmonary hypertension.
    Prior DL; Adams H; Williams TJ
    Med J Aust; 2016 Sep; 205(6):271-6. PubMed ID: 27627939
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Targeted Treatments for Pulmonary Arterial Hypertension: Interpreting Outcomes by Network Meta-analysis.
    Badiani B; Messori A
    Heart Lung Circ; 2016 Jan; 25(1):46-52. PubMed ID: 26233257
    [TBL] [Abstract][Full Text] [Related]  

  • 95. [Optimization of specific therapy for pulmonary hypertension: the possibilities of riociguat].
    Martynyuk TV; Shmalts AA; Gorbachevsky SV; Chazova IE
    Ter Arkh; 2021 Sep; 93(9):1117-1124. PubMed ID: 36286873
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Pharmacotherapeutic management of pulmonary arterial hypertension.
    Anderson JR; Nawarskas JJ
    Cardiol Rev; 2010; 18(3):148-62. PubMed ID: 20395700
    [TBL] [Abstract][Full Text] [Related]  

  • 97. The molecular targets of approved treatments for pulmonary arterial hypertension.
    Humbert M; Ghofrani HA
    Thorax; 2016 Jan; 71(1):73-83. PubMed ID: 26219978
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Advances in the discovery of drugs that treat pulmonary arterial hypertension.
    Zolty R
    Expert Opin Drug Discov; 2023 Apr; 18(4):445-466. PubMed ID: 37013267
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Overview of treprostinil sodium for the treatment of pulmonary arterial hypertension.
    Budev MM; Minai OA; Arroliga AC
    Drugs Today (Barc); 2004 Mar; 40(3):225-34. PubMed ID: 15148531
    [TBL] [Abstract][Full Text] [Related]  

  • 100. New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension.
    Mercurio V; Bianco A; Campi G; Cuomo A; Diab N; Mancini A; Parrella P; Petretta M; Hassoun PM; Bonaduce D
    Curr Med Chem; 2019; 26(16):2844-2864. PubMed ID: 29421995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.